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Perfluorooctanesulfonyl fluoride (POSF;
C8F17SO2F) was used to synthesize high-
molecular-weight fluorochemical products
manufactured by the 3M Company (3M).
Unique compounds were created by derivati-
zation of POSF through the sulfonyl ﬂuoride
moiety using conventional hydrocarbon reac-
tions (3M Company 2003). Although these
fluorochemical products tended to be stable
in the environment, secondary reactions pro-
ducing these polymers may have had unre-
acted or partially reacted starting materials or
intermediates that were carried forward to
the ﬁnal product. These ﬂuorochemical resid-
uals were typically present at a concentration
of ≤ 1% in the final commercialized prod-
ucts. These residuals could include N-methyl
perfluorooctanesulfonamidoacetate [M570;
C8F17SO2N(CH3)CH2COO–], N-ethyl
perﬂuorooctanesulfonamidoacetate [PFOSAA;
C8F17SO2N(CH2CH3)CH2COO–],
perfluorooctanesulfonamidoacetate (M556;
C8F17SO2NHCH2COO–), perﬂuorooctane-
sulfonamide (PFOSA; C8F17SO2NH2), per-
fluorooctanoate (PFOA; C7F15COO–), and
perﬂuorohexanesulfonate (PFHS; C6F13SO3
–).
M570 is an oxidation product of N-methyl
perfluorooctanesulfonamidoethanol [N-
MeFOSE; C8F17SO2N(CH3)CH2CH2OH], a
residual found in products used primarily in
surface treatment applications (e.g., carpets,
upholstery, textiles). Commercialization of this
product line began in the 1950s. PFOSAA is
an oxidation product of N-ethyl perfluoro-
octanesulfonamidoethanol [N-EtFOSE;
C8F17SO2N(CH2CH3)CH2CH2OH], a resid-
ual found in products of the phosphate ester
of N-EtFOSE that were primarily used in
paper and packaging protectant applications.
PFOSAA was also sold as a surfactant.
Commercialization of this product line
began in the late 1960s with the introduc-
tion of human food contact paper applica-
tions in 1974. Both PFOSAA and M570 are
thought to metabolize to M556 and PFOSA.
The terminal fluorochemical moiety of the
degradation pathway has been shown to be
perﬂuorooctanesulfonate (PFOS; C8F17SO3
–).
Unlike PFOSAA and M570, PFOS is not
specific to any consumer application, but
could stem from product or environmental
exposures.
Although PFOA and PFHS have been
analyzed as fluorochemical residuals in
POSF-based materials (Wendling 2003), the
primary role of these compounds was with
speciﬁc applications. PFOA was produced by
3M and other manufacturers to be an emulsi-
fier in a variety of industrial fluoropolymer
applications. PFOA may also be produced by
environmental degradation of some PFOS
precursors (Lange 2001) or by oxidation or
metabolism of the widely used telomer-based
ﬂuorochemicals manufactured by other com-
panies (Hagen et al. 1981). 3M produced
PFHS as a building block for compounds
incorporated in fire-fighting foams and spe-
ciﬁc postmarket carpet treatment applications.
In May 2000, 3M announced that it
would voluntarily cease manufacturing POSF-
based materials after PFOS was found to be
widespread in human populations and wildlife
[3M Company 2003; Giesy and Kannan
2001; Hansen et al. 2001; Kannan et al.
2001a, 2001b, 2002a, 2002b, 2002c, 2002d;
Organisation for Economic Co-operation and
Development (OECD) 2002]. 
The serum concentration of PFOS has
been reported to be, on average, 30–40 ng/mL
in nonoccupational human serum and liver
samples obtained in the United States (Hansen
et al. 2001; Olsen et al. 2003a, 2003b, 2004c,
2004d). Geographic differences may exist by
country (Kannan et al. 2004). In the largest
biomonitoring study of adults in the United
States (598 blood donors 20–69 years of age),
Olsen et al. (2003c) reported a geometric
mean (GM) serum PFOS concentration of
35 ng/mL [95% confidence interval (CI),
33–37 ng/mL]. The upper bound of the 95th
percentile estimate was 100 ng/mL. Adjusted
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The purpose of this investigation was to determine whether there has been a change in the human
blood concentration of perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), and five
other fluorochemicals since 1974. Blood samples were collected in 1974 (serum) and 1989
(plasma) from volunteer participants of a large community health study. The study included a
total of 356 samples (178 from each time period). These samples were analyzed by high-pressure
liquid chromatography/tandem mass spectrometry methods. The median 1974 and 1989 ﬂuoro-
chemical concentrations, respectively, were as follows: PFOS, 29.5 ng/mL vs. 34.7 ng/mL; PFOA,
2.3 ng/mL vs. 5.6 ng/mL; perfluorohexanesulfonate (PFHS), 1.6 ng/mL vs. 2.4 ng/mL; and
N-ethyl perﬂuorooctanesulfonamidoacetate (PFOSAA), less than the lower limit of quantitation
(LLOQ; 1.6 ng/mL, vs. 3.4 ng/mL). For N-methyl perfluorooctanesulfonamidoacetate (M570),
perfluorooctanesulfonamide, and perfluorooctanesulfonamidoacetate, median serum concentra-
tions in both years were less than the LLOQ values (1.0, 1.0, and 2.5 ng/mL, respectively).
Statistical analysis of 58 paired samples indicated that serum concentrations of PFOS, PFOSAA,
PFOA, PFHS, and M570 were signiﬁcantly (p < 0.001) higher in 1989 than in 1974. The data
from 1989 were then compared with geometric mean fluorochemical concentrations of serum
samples collected in 2001 from 108 American Red Cross adult blood donors from the same
region. Except for M570, there were no statistically signiﬁcant (p < 0.05) geometric mean ﬂuoro-
chemical concentration differences between the 1989 and 2001 samples. In conclusion, based on
this study population, PFOS and other serum fluorochemical concentrations have increased
between 1974 and 1989. Comparison with other regional data collected in 2001 did not suggest a
continued increase in concentrations since 1989. Key words: fluorochemicals, perfluorohexane-
sulfonate, perfluorooctanesulfonate, perfluorooctanoate, PFHS, PFOA, PFOS. Environ Health
Perspect 113:539–545 (2005). doi:10.1289/ehp.7544 available via http://dx.doi.org/ [Online
2 February 2005]for age and sex, there were minimal differences
between the six locations from which the sam-
ples were obtained. Similar ﬁndings for PFOS
have been reported in children and the elderly
(Olsen et al. 2004a, 2004b). After considera-
tion of serum and liver PFOS concentrations
associated with no observed adverse effect lev-
els (NOAEL) and benchmark dose calculations
from several toxicologic studies, a human
serum concentration of 100 ng/mL PFOS (the
upper bound estimate of the 95th percentile
observed in the children, adult, and elderly
populations studied in the United States
described above) was related to margins of
exposure ranging from 310 (decreased rat pup
weight gain) to 1,550 (liver tumors in adult
rats) (3M Company 2003). 
Although not fully understood, the path-
ways leading to the presence of PFOS in
serum and tissue in the general population
include release to the environment of POSF-
based materials in the waste streams generated
from the manufacturing processes and supply
chain operations, and/or exposures to con-
sumer products (3M Company 2003; Hansen
et al. 2002; Martin et al. 2002; OECD 2002).
The other six fluorochemicals mentioned
above have also been quantiﬁed in the general
population at concentrations that are approxi-
mately an order of magnitude lower than that
of PFOS (Olsen et al. 2003c, 2004a, 2004b).
In occupationally exposed populations, serum
PFOS concentrations have averaged between
500 and 2,000 ng/mL, depending on the type
of job (Olsen et al. 2003a, 2003b).
An extensive PFOS-related toxicology
database is reviewed elsewhere (3M Company
2003; OECD 2002). Studies in rats show that
PFOS is well absorbed orally and distributes
primarily in the liver and, to a lesser extent, in
the serum/plasma of rats (Johnson et al.
1979). Substantial enterohepatic circulation of
PFOS occurs with both urinary and fecal
excretion (Johnson et al. 1984). Dermal
absorption of PFOS appears to be possible but
limited (3M Company 2003). Because of the
exceptionally low vapor pressure of PFOS,
inhalation exposure to vapor would be
unlikely. If inhalation exposure does occur, it
would be most likely associated with aerosols
or particulates containing PFOS. In the pro-
duction of PFOS and related chemistries,
exposure to the volatile PFOS precursor POSF
was possible. In addition to POSF, certain
other precursor molecules, such as N-EtFOSE
and N-MeFOSE, are known to sublime.
These precursors may represent a more likely
inhalation exposure pathway than exposure to
PFOS itself (3M Company 2003). 
Mechanisms of toxicity in the animal
studies are not fully understood but may
include effects on fatty acid transport and
metabolism, membrane function and mito-
chondrial bioenergetics (Berthiaume and
Wallace 2002; Haughom and Spydevold
1992; Hu et al. 2002; Luebker et al. 2002;
Starkov and Wallace 2001). Lowered serum
total cholesterol appeared to be a consistent
early ﬁnding, with cumulative toxicity result-
ing in metabolic wasting and ultimately death
in laboratory animals exposed to high doses
(Seacat et al. 2002a, 2002b, 2003). Two-year
feeding studies of PFOS in rats produced a
modest, largely benign, liver tumor response
in the high-dose group (20 ppm PFOS in
feed), which likely occurred through nongeno-
toxic mechanisms (Seacat et al. 2002a). PFOS
reduced postnatal survival and body weight
gains in dams and pups in reproduction and
development studies of mice and rats (Lau
et al. 2003; Thibodeaux et al. 2003). In utero
exposure is likely in humans because a high
correlation (r2 = 0.9) of PFOS concentrations
(range, 5–18 ng/mL) was shown in 15 mater-
nal and cord blood samples from Japan (Inoue
et al. 2004).
As reviewed by Kennedy et al. (2004),
ingestion, inhalation, and dermal pathways are
potential pathways of absorption for PFOA
and there are marked pharmacokinetic differ-
ences by species and by sex within some
species. PFOA is a peroxisome proliferator and
exerts morphologic and biochemical effects
characteristic of peroxisome proliferator-α
receptor (PPAR) agonists. These effects
included increased β-oxidation, increases in
several cytochrome P-450–mediated reactions,
and inhibition of the secretion of very-low-
density lipoproteins and cholesterol from the
liver (Kennedy et al. 2004). The triad of
tumors observed (liver, Leydig cell, and pancre-
atic acinar cell tumors) in a lifetime bioassay
study of rats fed PFOA is typical of many
PPAR agonists and is believed to involve
nongenotoxic mechanisms (Biegel et al. 2001;
Kennedy et al. 2004; Klaunig et al. 2003).
After consideration of serum and liver PFOA
concentrations associated with NOAELs and
benchmark dose calculations from several toxi-
cologic studies, a human serum concentration
of 14 ng/mL PFOA (the upper bound estimate
of the 95th percentile observed in the children,
adult, and elderly populations studied in the
United States described above) was related to
margins of exposure between 1,600 (liver
weight increase in rats) to 8,900 (Leydig cell
adenoma) (Butenhoff et al. 2004). 
Although current serum PFOS and
PFOA concentrations have been characterized
(Olsen et al. 2003c, 2004a, 2004b), few sam-
ples have been analyzed to determine tempo-
ral trends in serum concentrations in the
general population (3M Company 2003). In
one analysis, PFOS was not detected in
10 pooled samples (10 donors per sample)
from U.S. military recruits of the Korean War
era, a period just before the commercial intro-
duction of POSF-based materials (3M
Company 2003). The purpose of the present
investigation was to assess whether blood con-
centrations of PFOS, PFOA, and five other
ﬂuorochemicals may have increased during a
27-year time period in a selected sample of a
general population. Repository blood samples
were obtained from participants of a commu-
nity study conducted in 1974 and 1989 in
Washington County, Maryland (Comstock
et al. 1988, 1997), whose county seat is
Hagerstown. These ﬁndings were then com-
pared with 108 American Red Cross adult
blood donor samples collected from the
Hagerstown area in 2001 whose GM serum
level was 35 ng/mL (95% CI, 32–39) with a
range of 8–226 ng/mL (Olsen et al. 2003c).
Materials and Methods
Study population. Blood samples were obtained
from two large community-based cohorts estab-
lished in Washington County, Maryland, in
1974 and 1989 for studying clues to the
development of heart disease and cancer. The
volunteer participants were asked to donate a
blood sample and respond to a brief question-
naire that inquired about demographic charac-
teristics and health-related variables. Among
the donors, there were 5,497 and 2,172 partic-
ipants in 1974 and 1989, respectively, who
were not in the subsequent analytical cohort
(residents within a 30-mile radius of the study
center), and the samples were eligible to be
used for the present study. Most of these partic-
ipants were from geographic communities con-
tiguous to Washington County in Maryland,
Pennsylvania, West Virginia, or Virginia. The
present study was approved by the Committee
on Human Research of the Johns Hopkins
Bloomberg School of Public Health.
The serum samples (collected in 1974)
and plasma samples (collected in 1989) of
these out-of-county residents were stored at
–70°C until thawed for the present study. A
total of 356 blood samples (178/year) were
randomly selected across sex and 10-year age
strata. Fifty-eight individuals participated in
both years providing paired samples. These
58 individuals were selected to examine
within-person change levels with a statistical
power of 85% to detect a 10% change
between 1974 and 1989. The nonpaired sam-
ples (120/year) were selected with 80% statis-
tical power to detect a 20% change, stratiﬁed
by sex and age groups of < 40, 40–60, and
> 60 to ensure equal numbers in each stratum.
Laboratory assay. A selective and sensitive
method for analysis of PFOS, PFOA, PFHS,
PFOSAA, M570, M556, and PFOSA in
human serum and plasma, using liquid chro-
matography/tandem mass spectrometry, was
developed and validated (Tandem Labs 1999,
2001a, 2001b). The results of the human
serum and plasma validation experiments com-
plied with the precision and accuracy limits
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by the U.S. Food and Drug Administration
(FDA) guidance document (FDA 2001).
Additionally, serum quality control sam-
ples were analyzed against plasma calibration,
because plasma has lower endogenous levels of
some analytes than does serum. This method
of quantitating serum samples against plasma
calibration also met the FDA ± 15% method
precision requirement for all target analytes
and also met the FDA ± 15% method accu-
racy requirement for PFOS, M556, and
M570. Method accuracy for serum analysis
against plasma calibration was expanded to
± 19% for PFOA, ± 21% for PFOSAA, and
± 26% for PFHS. Method accuracy for serum
analysis against plasma calibration was less
acceptable for PFOSA at 43%.
Together, these validations showed that
the method is valid for the quantitation of
human sera samples using calibration curves in
serum, as well as using calibration curves in
plasma (Tandem Labs 1999, 2001a, 2001b).
Although the use of plasma for the quantita-
tion of sera samples does not strictly meet the
FDA requirements for accuracy for the target
analytes except PFOS, M556, and M570, the
validations showed that the only difference
that it introduced was a relatively small sys-
tematic bias while maintaining excellent preci-
sion. This bias may be corrected for, if desired.
This correction was not deemed necessary for
the purposes of biomonitoring studies per-
formed by 3M. A validation study of the
methods used in the present study also
demonstrated stability of the analytes regard-
ing the number of freeze/thaw cycles (Tandem
Labs 1999, 2001a, 2001b).
The specific analytical methods used for
the analysis of these ﬂuorochemicals in human
serum samples have been described previously
(Olsen et al. 2003c, 2004a, 2004b) and for the
purpose of brevity are not detailed here. A
report describing the speciﬁc analyses done in
the present study is available (Tandem Labs
2001c). Briefly, the method used to analyze
serum and plasma samples consisted of a liq-
uid:liquid extraction procedure followed by
evaporation and reconstitution of the extract
residue with 20 mM ammonium acetate in
water:20 mM ammonium acetate in methanol
(30:70, vol/vol). The samples were analyzed
by liquid chromatography/tandem mass
spectrometry using an API 3000 (Applied
Biosystems, Foster City, CA). The instrument
was operated in the multiple reaction monitor-
ing mode under optimized conditions for the
PFOS, PFOA, PFHS, PFOSAA, PFOSA,
M556, and M570 detection of the negative
ions formed by TurboIonSpray ionization
(Applied Biosystems, Foster City, CA).
Quantitation of the target analytes in serum
samples was performed by comparing the chro-
matographic peak areas for each compound
with those generated in a series of extracted
calibration standards prepared from control
plasma determined to contain < 4 ng/mL of
any of the target analytes. Evaluation of quality
control samples injected during the analytical
runs of the 356 samples indicated that the
reported quantitative results may have varied
± 10% for precision and accuracy (Tandem
Labs 2001c). The repeatability of ﬂuorochemi-
cal analyses was assessed by nine pairs of identi-
cal samples that were randomly inserted into
vial arrays for analyses. The intraset coefﬁcients
of variation for the fluorochemical measure-
ments on 1974 and 1989 samples ranged from
3–5% and 3–8%, respectively.
The same analytical methods and labora-
tory were used in both the present investiga-
tion and the analysis of the Hagerstown
samples collected in 2001 (Olsen et al. 2003c),
although the latter were not analyzed concur-
rently with the present study samples.
Data analysis. PFOS was the only ﬂuoro-
chemical for which all samples had concentra-
tions above the lower limit of quantitation
(LLOQ). For statistical analysis, values of
other ﬂuorochemicals < LLOQ were assigned
the midpoint between zero and the LLOQ.
Using the Wilcoxon rank sum test, we
assessed whether concentrations of fluoro-
chemicals differed by sex or age (< 40, 40–60,
and > 60 years). Among the 58 paired sam-
ples, we assessed the changes in fluoro-
chemicals over time using the Wilcoxon
signed-rank test. Median regression models
were used to assess whether concentrations
were different by the two time points, with
and without adjustment for sex and age.
Because PFOSAA and M570 are metabo-
lized to M556 and PFOSA and then to PFOS,
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Table 1. Demographic characteristics of study participants.
Characteristic 1974 (n = 178) 1989 (n = 178) p-Valuea
Age (years)
Median (IQR) 47.5 (30–60) 52 (39–65) 0.007b
Sex [no. (%)]
Male 87 (49) 86 (48)
Female 91 (51) 92 (52) 0.92c
Education, years [no. (%)]
< 12 61 (34) 38 (21)
12 63 (35) 63 (35) 0.08
> 12 53 (30) 77 (43) 0.002
Missing data 1 (1) 0 (0) —
Cigarette smoking [no. (%)]
Never 85 (48) 90 (51)
Former 51 (29) 52 (29) 0.88
Current 42 (24) 36 (20) 0.44
aMixed logistic regression model that included paired and nonpaired samples. bAge not signiﬁcantly different when only
nonpaired data analyzed. cLogistic model included only nonpaired samples.
Table 2. Serum concentrations (ng/mL) of ﬁve ﬂuorochemicals in 1974: summary data of 178 samples.
Analyte LLOQa > LLOQ [n (%)] Median (IQR) GM (95% CI)
PFOS 3.9 178 (100) 29.5 (21.1–40.2) 30.1 (27.8–32.6)
PFOSAA 1.6 58 (33) 0.8 [LLOQ (1.6)–1.8] 1.2 (1.1–1.3)
M570 1.0 7 (4) 0.5 [< LLOQ (1.0)]b 0.5 (0.5–0.6)
PFOA 1.9 127 (71) 2.3 [< LLOQ (1.0)–3.0] 2.1 (1.9–2.2)
PFHS 1.4 112 (63) 1.6 [(< LLOQ (1.4–2.5)] 1.5 (1.3–1.6)
aValues < LLOQ were imputed as midpoint between zero and the LLOQ. bAll M570 values in the interquartile range were
< LLOQ (1.0).
Table 3. Serum concentrations (ng/mL) of ﬁve ﬂuorochemicals in 1974 by sex and age.
By sex By age
Male (n = 87) Female (n = 91) Age < 40 (n = 66) Age 40–60 (n = 67) Age > 60 (n = 45)
Analyte [median (IQR)] [median (IQR)] p-Valuea  [median (IQR)] [median (IQR)] [median (IQR)] p-Valuea
PFOS 32.8 (23.3–42.8) 25.3 (20.0–35.9) 0.01 24.8 (20.1–34.6) 31.7 (23.0–39.0) 35.3 (25.1–50.3) 0.02
PFOSAA 0.8 [< LLOQ (1.6)–1.9] 0.8 [< LLOQ (1.6)–1.8] 0.63 0.8 (0.8–2.0) 0.8 (0.8–1.7) 0.8 (0.8–1.6) 0.08
M570 0.5 [< LLOQ (1.0)] 0.5 [< LLOQ (1.0)] 0.75 0.5b 0.5b 0.5b 0.87
PFOA 2.4 (1.0–3.0) 2.3 (1.0–3.1) 0.53 2.2 (0.9–2.7) 2.4 (0.9–3.0) 2.4 (0.9–3.2) 0.39
PFHS 1.9 [< LLOQ (1.4)–3.1] 1.4 [< LLOQ (1.4)–2.2] < 0.0001 0.7 [< LLOQ (1.4)–1.7] 1.9 (0.7–2.6) 2.2 (1.6–3.0) < 0.0001
aWilcoxon rank sum test. bAll M570 values in the IQR were < LLOQ (1.0).we explored whether concentrations of the
precursor compounds, PFOSAA or M570,
correlated with or predicted concentrations of
PFOS, using median regression models.
In order to minimize parametric assump-
tions in the estimation of extreme percentiles
of the population, we used the statistical
bootstrap method of Efron and Tibshirani
(1993) to generate confidence limits around
the empirical percentiles for serum concentra-
tions in the two time periods. In this method,
a large number of replicated estimates of the
percentile are generated from full-size samples
of the original observations drawn with
replacement. The distribution of the devia-
tions of replicates from the original-sample
estimate mimics the underlying sampling dis-
tribution for the estimate. Bias-corrected,
accelerated percentiles were used to minimize
residual bias. The bias correction factor is
derived by comparing empirical percentiles
with bootstrap percentiles, and acceleration is
accomplished by partial jackknifing. Olsen
et al. (2003c, 2004a, 2004b) employed iden-
tical estimation methodology in their analyses
of children, adult, and elderly samples.
Results
The demographic characteristics of the study
participants are presented in Table 1. About
half were men and half never smoked ciga-
rettes. The percentages of blood samples in
1974 that were quantifiable along with the
medians and interquartile ranges (IQRs), and
GMs and 95% CIs, of the fluorochemicals
measured are presented in Tables 2–3. Data
for PFOSA and M556 are not presented
because all samples collected in 1974 were
reported at < LLOQ, 1.0 and 2.5 ng/mL,
respectively, for these two analytes. Median
concentrations of PFOS and PFHS were sta-
tistically significantly (p < 0.05) higher in
men than in women in 1974, whereas no sex-
related differences in PFOSAA, PFOA, or
M570 concentrations were observed. Median
PFOS and PFHS concentrations were signiﬁ-
cantly lower in individuals younger than
40 years of age (Tables 2 and 3).
The percentages of blood samples in 1989
that were quantiﬁable along with the medians
and IQRs, and GMs and 95% CIs of the ﬂuo-
rochemicals measured are presented in Tables 4
and 5. Data for PFOSA and M556 are also not
presented in Tables 4 and 5 because all PFOSA
values and 96% of the M556 values were
reported at < LLOQ, 1.0 and 2.5 ng/mL,
respectively. Median concentrations of PFOS
and PFHS were statistically signiﬁcantly higher
in men than in women in 1989, whereas no
sex-related differences in PFOSAA, PFOA, or
M570 concentrations were observed. Median
serum concentrations for PFOA and PFHS
were also signiﬁcantly lower in persons younger
than 40 years of age in 1989. Statistically signif-
icant differences by age were not observed for
PFOS, PFOSAA, or M570.
Among the 58 individuals who donated
blood at both time periods, the median con-
centrations of PFOS, PFOSAA, PFOA, PFHS,
and M570 were statistically signiﬁcantly higher
in 1989 than in 1974 (Table 6). Among the
120 samples collected from different individu-
als in 1974 and 1989, PFOSAA, PFOA, and
PFHS were signiﬁcantly higher in 1989 than
in 1974, adjusted for age and sex (Table 7). It
was not possible to add smoking and education
to the model because the iterations did not
converge.
Because PFOSAA and M570 are fluoro-
chemical residuals that may degrade to some
unknown degree to PFOS, we examined the
correlations between these compounds. In the
median regression models for the 1989 data
with PFOS as the dependent variable, the
regression coefficient was 0.73 (p < 0.0001)
for PFOSAA and 2.98 (p = 0.018) for M570.
In contrast, no statistically signiﬁcant associa-
tions were observed in 1974. We also
examined the association between PFOS and
PFOA because these two compounds were
reported to be highly correlated in other stud-
ies (Olsen et al. 2003d, 2004a, 2004b).
Spearman correlations between PFOS and
PFOA were 0.53 (p < 0.0001) in 1974 and
0.60 (p < 0.0001) in 1989.
A food frequency questionnaire was com-
pleted by 51 of the 178 participants who pro-
vided blood samples in 1989. We evaluated
these data to determine if there was an associa-
tion between fast-food consumption and
plasma PFOSAA concentrations because our
hypothesis was that those who consumed
more fast food may have been exposed to
N-EtFOSE residuals that may be found in
paper or package protectants applied to wrap-
pings in take-out food operations. No statisti-
cally signiﬁcant differences were observed for
median plasma PFOSAA concentrations
(metabolite of N-EtFOSE) for those who ate
foods between once a week and once a day
compared with less than once a week for ham-
burgers (2.8 vs. 4.1 ng/mL), fried chicken (3.4
vs. 5.7 ng/mL), pizza (3.4 vs. 3.5 ng/mL), and
fried ﬁsh (3.6 vs. 3.6 ng/mL), respectively.
The results from statistical bootstrap
analyses conducted to provide estimates of
upper tolerance limits of the distributions are
presented in Table 8. The upper tolerance
limits represent the concentration of each
fluorochemical below which the stated pro-
portion of the population is expected to be
found. Presented are the biased corrected esti-
mates for the 90%, 95%, and 99% upper tol-
erance limits of the ﬁve ﬂuorochemicals along
with the upper limit (bound) from the
95% CI. For example, the bias-corrected esti-
mate of the upper 95% tolerance limit for
PFOS in 1974 was 73 ng/mL with an upper
95% conﬁdence limit of 112 ng/mL.
Figure 1 shows the median and IQRs of
the ﬂuorochemical concentrations in the pre-
sent study compared with the 2001 results
reported for 108 Hagerstown area subjects
(median age, 48 years; 55% male, 45%
female) analyzed by Olsen et al. (2003c). Most
samples were measured above the LLOQ in
each year for PFOS and PFOA. GMs (and
95% CIs) for PFOS in 1974, 1989, and 2001
were 30.1 ng/mL (27.8–32.6), 33.3 ng/mL
(31.1–35.6), and 35.3 ng/mL (31.8–39.1),
respectively, with the 2001 GM statistically
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Table 4. Plasma concentrations (ng/mL) of ﬁve ﬂuorochemicals in 1989: summary data of 178 samples. 
Analyte LLOQa > LLOQ [n (%)] Median (IQR) GM (95% CI)
PFOS 3.9 178 (100) 34.7 (25.0–44.0) 33.3 (31.1–35.6)
PFOSAA 1.6 166 (93) 3.4 (2.5–4.7) 3.6 (3.2–4.0)
M570 1.0 68 (38) 0.5 [< LLOQ (1.0)–1.3] 0.8 (0.7–0.9)
PFOA 1.9 177 (99) 5.6 (4.4–6.7) 5.5 (5.2–6.9)
PFHS 1.4 145 (82) 2.4 (1.3–1.6) 2.5 (2.2–2.8)
aValues < LLOQ were imputed as midpoint between zero and the LLOQ.
Table 5. Plasma concentrations (ng/mL) of ﬁve ﬂuorochemicals in 1989 by sex and age.
By sex By age
Male (n = 86) Female (n = 92) Age < 40 (n = 45) Age 40–60 (n = 67) Age > 60 (n = 66)
Analyte [median (IR)] [median (IQR)] p-Valuea [median (IQR)] [median (IQR)] [median (IQR)] p-Valuea
PFOS 38.3 (31.7–50.0) 30.4 (21.3–41.0) 0.0003 33.3 (27.0–44.1) 33.6 (25.3–41.5) 35.1 (24.5–50.0)  0.99
PFOSAA 3.4 (2.6–4.6) 3.2 (2.5–4.9) 0.67 3.4 (2.6–5.2) 3.3 (2.5–4.7) 3.4 (2.3–4.6) 0.72
M570 0.5 [< LLOQ (1.0)–1.4] 0.5 [< LLOQ (1.0)–1.3] 0.21 0.5 [< LLOQ (1.0)–1.6] 0.5 [< LLOQ (1.0)–1.1] 0.5 [< LLOQ (1.0)–1.4] 0.23
PFOA 5.8 (4.8–6.8) 5.5 (3.6–6.7) 0.11 5.3 (3.6–6.3) 5.5 (4.4–6.8) 6.0 (4.8–7.2) 0.01
PFHS 2.8 (2.2–4.2) 2.1 [< LLOQ (1.4)–3.1] 0.003 1.8 [< LLOQ (1.4)–2.6] 2.5 (1.4–4.2) 3.0 (2.2–5.2)  0.0003
aWilcoxon rank sum test.significantly different than the 1974 but not
1989 values. GMs (and 95% CIs) for PFOA in
1974, 1989, and 2001 were 2.1 ng/mL
(1.9–2.2), 5.5 ng/mL (5.2–5.9), and 4.2 ng/mL
(3.8–4.8), respectively, with each year being sig-
niﬁcantly different than the other years. It was
not possible to adequately detect trends over
this 27-year time period for PFHS, PFOSAA,
and M570 because of the large number of sam-
ples in each year that were below the LLOQ
and because, when compared with the present
study, higher LLOQ values were used (< 2.1,
< 2.8, and < 1.8 ng/mL, respectively) with the
2001 samples analyzed by Olsen et al. (2003c).
Nevertheless, the median and IQRs appear not
to have substantially increased (Figure 1).
Discussion
Our data indicate that PFOS concentrations
increased in this population between 1974 and
1989. Based on the 58 paired samples in the
present study, the median PFOS concentration
in the blood (serum or plasma) increased 25%
from 1974 (median, 24.9 ng/mL) to 1989
(median, 33.2 ng/mL). For the nonpaired sam-
ples, a statistically nonsigniﬁcant 9% difference
in median values was observed between 1974
(median, 32.8 ng/mL) and 1989 (median,
35.7 ng/mL). The change in the paired and
nonpaired sample results are not directly com-
parable because the findings may be con-
founded by age. In 1974, age was lower for
the paired samples compared with nonpaired
samples (mean ± SD of 42.3 ± 12.3 vs.
47.8 ± 19.1, respectively). In 1989 age was
signiﬁcantly higher in the paired samples com-
pared with the nonpaired samples (mean ± SD
of 57.2 ± 12.6 vs. 48 ± 17.5, respectively).
The distribution by sex was similar for the
paired and nonpaired samples in each year.
Because the paired sample group represents
within-person change over time, unlike the
nonpaired samples, and were chosen a priori
to specifically examine this issue, we believe
these data analyses support the inference of the
occurrence of a change in PFOS concentra-
tions in our study population between 1974
and 1989. This change in concentration may
be due to increased exposure (consumer or
environmental) and/or bioaccumulation.
Production of POSF-derived products
increased substantially (5-fold) between 1975
and 1989 (Santoro M, personal communica-
tion), and the number of applications for those
products also increased, including the use in
human food contact applications. PFOS con-
centrations were lower in the younger
(< 40 years) age range in 1974 compared with
the older age categories. This association was
not observed in 1989. A speculative explana-
tion could be that this younger age category in
1974 may have had less opportunity for
potential exposure to some POSF-based prod-
uct lines, environmental exposure, or even
in utero exposure (Inoue et al. 2004) than the
same age category 15 years later.
PFOS concentrations may not have
increased since 1989 because the median values
of the paired and nonpaired samples approxi-
mated the median value (36 ng/mL) of
108 samples of American Red Cross blood
donors from the Hagerstown area that were
collected in 2001 (Olsen et al. 2003c). These
108 Hagerstown area donors were comparable
in age and sex to those individuals analyzed in
1974 and 1989. This median PFOS concen-
tration among the Hagerstown donors was also
similar to ﬁve other geographic locations meas-
ured by Olsen et al. (2003c). Statistical boot-
strap estimates of the upper bound of the 95th
percentile of PFOS in the 1974 and 1989 time
periods do not indicate a shift in the upper tail
of the distribution of serum PFOS concentra-
tions when compared with the Hagerstown
2001 data. The upper bound estimate in the
present study was 112 ng/mL in 1974 and
69 ng/mL in 1989, and was reported as
100 ng/mL based on 645 American Red Cross
adult blood donors collected in 2001 by Olsen
et al. (2003c). Although any explanation for the
similar serum PFOS concentrations measured
in 1989 and 2001 from residents living in prox-
imity to Hagerstown would be speculative, one
possibility could be the relatively consistent pro-
duction of POSF that occurred between 1989
and 1999 (the year before 3M’s voluntary
phase-out announcement) (Santoro M, per-
sonal communication). This might explain the
relative steady-state serum concentrations in
these populations that would have been
obtained from various potential sources of
exposure (consumer and environmental) dur-
ing this time period. By comparison, total
worldwide POSF production by 3M was
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Table 6. Changes in serum ﬂuorochemical concentrations (ng/mL) from 1974 to 1989 in 58 paired samples.
1974 1989 Percent
Analyte mediana (IQR) mediana (IQR) differenceb p-Valuec
PFOS 24.9 (20.5–34.4) 33.2 (24.8–41.1) 25 0.0003
PFOSAA 0.8 [< LLOQ (1.6)–2.0] 3.4 (2.5–5.0) 204 < 0.0001
M570 0.5 [< LLOQ (1.0)] 0.5 [< LLOQ (1.0)] 0 < 0.0001d
PFOA 2.3 (1.0–2.8) 5.6 (4.3–6.9) 162 < 0.0001
PFHS 1.5 [< LLOQ (1.4)–1.9] 2.1 (1.5–3.1) 57 < 0.0001
aValues < LLOQ were imputed as midpoint between zero and the LLOQ (LLOQ values are presented in Tables 2 and 4).
bMedian percent difference for within-subject changes. cp-Value from Wilcoxon signed-rank test for paired samples analy-
sis. dAlthough the median value for M570 is the same for both years, the p-value is based on 41% of paired samples
increased to only 3% decrease (the rest remained the same).
Table 7. Changes in fluorochemical concentrations (ng/mL) from 1974 to 1989 in nonpaired samples
adjusted for age and sex (n = 120 samples/year).
1974 1989 Percent
Analyte mediana (IQR) mediana (IR) differenceb p-Valuec
PFOS 32.8 (21.9–45.0) 35.7 (25.3–45.8) 9 0.50
PFOSAA 0.8 [< LLOQ (1.6)–1.8] 3.4 (2.5–4.4) 324 < 0.0001
M570 0.5 [< LLOQ (1.0)] 0.5 [< LLOQ (1.0)–1.3] 0 1.0
PFOA 2.4 (1.0–3.0) 5.7 (4.4–6.7) 138 < 0.0001
PFHS 1.8 [< LLOQ (1.4)–2.6] 2.6 (1.8–4.2) 46 < 0.0001
aValues less than the LLOQ were imputed as midpoint between zero and the LLOQ (LLOQ values are presented in Tables 2
and 4). bPercent median difference. cp-Value from a median regression analysis adjusted for age and sex.
Table 8. Estimates (ng/mL) of upper tolerance limits and upper confidence limits for five serum fluoro-
chemicals, 1974 and 1989.
1974 1989
Upper tolerance Upper limit Upper limit 
Fluorochemical limit (%) Estimatea of 95% CI Estimatea of 95% CI
PFOS 90 57 68 59 62
95 73 112 65 69
99 140 178 82 123
PFOSAA 90 3 3 8 11
95 4 5 14 29
99 7 13 52 127
M570 90 LLOQa LLOQa 23
95 LLOQa LLOQa 34
99 3 5 5 6
PFOA 90 4 4 9 10
95 5 6 11 13
99 6 8 21 72
PFHS 90 4 4 8 10
95 5 6 12 15
99 7 11 33 65
aEstimated value at < LLOQ (1.0 ng/mL). reduced 20-fold in 2001 compared with 2000,
the year of the company’s voluntary phase-out
announcement.
Since the 1960s several studies have
reported total organic ﬂuorine concentrations
in human blood from presumably non-
occupationally exposed persons. Guy (1972),
Singer and Ophaug (1979), and Taves et al.
(1976) reported mean total organic fluorine
concentrations of 30 (n = 65), 25 (n = 106),
and 45 (n = 264) ppb, respectively. Using
nuclear magnetic resonance spectroscopy,
Taves (1968a, 1968b; Taves et al. 1976) deter-
mined organic ﬂuorine was bound to albumin
and tentatively identiﬁed a component of the
organic fluorine as PFOA but also hypothe-
sized that branching or the presence of a sul-
fonate was a possible interpretation of their
ﬁndings. To compare measured PFOS concen-
trations in serum with total organic fluorine
values, PFOS can be multiplied by the fraction
of the molecular weight (0.65) contributed by
the carbon-bound fluorine. If done for the
median values reported in the present study
(Tables 2–5), this yields 19 and 23 ppb organic
ﬂuorine for 1974 and 1989, respectively. This
indicates that the 1974 serum PFOS results
reported herein are consistent with the infer-
ence that PFOS was likely the predominant
organoﬂuorochemical in the serum at the time.
Whether measured in the paired or non-
paired samples, there was a 4-fold increased
concentration of PFOSAA in 1989 compared
with 1974. This difference may be due to vari-
ous factors, including as one hypothesis that the
increase related to the commercialized use of
the phosphate ester of N-EtFOSE–related
products as protective coating on paper used for
human food contact applications that began in
1974. However, we were unable to show an
association between serum PFOSAA concentra-
tions and frequency of fast-food consumption
(where N-EtFOSE–related paper protectants
might have been used) in 1989, albeit this was a
small subset of study subjects. No increase in
median serum PFOSAA concentrations was
seen between the 1989 and 2001 data for this
area (Figure 1).
M570 serum concentrations may have
increased between 1974 and 1989 with 93%
of the samples < LLOQ in 1974 compared
with 61% < LLOQ in 1989. Median values
remained the same between these 2 years.
Most M570 samples measured in 2001 from
the 108 Hagerstown blood donors were
< LLOQ (measured at either 1.0 or
1.8 ng/mL depending upon the batch analy-
sis) (Olsen et al. 2003c).
Because they are metabolized quickly
and have relatively short serum elimination
half-lives (Butenhoff J, personal communica-
tion), PFOSAA and M570 as serum concen-
trations should be considered markers for
only recent nonoccupational exposure in the
general population. This is unlike PFOS,
PFOA, and PFHS, which have estimated
serum elimination half-lives of several years
(Burris et al. 2002). Because the commer-
cialization of N-EtFOSE–related products
for human food packaging applications did
not commence until the mid-1970s, our
data also suggest that human PFOS serum
concentrations observed in 1974 were likely
from either environmental origin and/or
from N-MeFOSE–related products that
were commercially introduced in the 1950s.
Our study data also indicate that serum
PFOA may have also increased by a few
nanograms per milliliter between 1974 and
1989 representing a 2-fold rise although the
source was not determined. The subset analy-
sis of the 58 paired samples supports this
approximate 2-fold increase in serum PFOA
concentrations since 1974. This trend may
not have continued into the more recent time
period because the median PFOA value was
4.5 ng/mL among the 108 Hagerstown,
Maryland (Washington County), blood
donors in 2001, similar to that measured in
the present study in 1989.
We observed statistically signiﬁcant corre-
lations between PFOS and PFOA in both
time periods. These were similar to the corre-
lations (Pearson correlation coefﬁcient ~ 0.7)
reported in more recently collected blood
samples from children, adults, and elderly in
the United States (Olsen et al. 2003c, 2004a,
2004b). These associations between PFOS
and PFOA are of interest because PFOA is
not known to convert directly from PFOS (or
vice versa). Whether these statistical associa-
tions are due to the presence of PFOA as a
by-product in POSF-related production or to
other nonrelated environmental exposures or
consumer products (e.g., higher chain telom-
ers) remains to be determined.
Several limitations could exist in this study.
First, serum was the medium analyzed in
1974, versus plasma in 1989. The validated
study of the analytical methods, however, pro-
vided comparable ﬁndings regardless of serum
or plasma (Tandem Labs 1999, 2001a,
2001b). Conjugated forms of PFOSAA and
M570, if they exist, were not accounted for in
these analyses. Systematic biases were mini-
mized between the 1974 and 1989 laboratory
analyses because the samples were measured
concurrently, although freezer storage time was
different. Comparison of our 1974 and 1989
data with the American Red Cross adult blood
donor data from Hagerstown, Maryland, col-
lected in 2001 (Olsen et al. 2003c) allows for
the potential for possible drift in laboratory
results because of a different time of analysis,
although the same analytical method and labo-
ratory were used. Many samples were meas-
ured below the LLOQ of the assay for some of
the analytes; thus, measures of central tendency
for the population distributions were not exact.
This was not the case, however, for PFOS for
either time period or for PFOA, PFOSAA, and
PFHS in 1989.
In conclusion, the present study was
designed to assess the concentration trends of
PFOS, PFOA, and ﬁve other ﬂuorochemicals
in blood samples from individuals in the gen-
eral population who resided near Washington
County, Maryland, between 1974 and 1989.
Analysis of blood samples collected from the
same 58 individuals indicated the median
PFOS concentration increased 25% (~ 10
ng/mL). Among the same individuals,
PFOSAA and PFOA increased a few nano-
grams per milliliter between 1974 and 1989,
which resulted in a 2-fold increase in concen-
trations. A comparison with other regional
data collected in 2001 did not suggest a con-
tinued increase in concentrations since 1989.
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